Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature.

Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, USA.
American Journal of Psychiatry (Impact Factor: 13.56). 11/2001; 158(10):1617-22. DOI: 10.1176/appi.ajp.158.10.1617
Source: PubMed

ABSTRACT The delayed onset of therapeutic response to antidepressants remains a major problem in the treatment of depression. Among the strategies to accelerate response to treatment, the early addition of thyroid hormone to antidepressants has been suggested as a viable method. The authors performed a meta-analysis of the literature on the use of thyroid hormone supplementation to accelerate the treatment of depression to determine whether there is sufficient evidence to support the clinical efficacy of this strategy.
Both a computer-aided search of the National Library of Medicine MEDLINE and an intensive search by hand were conducted to identify all double-blind, placebo-controlled studies assessing the concomitant administration of thyroid hormone and antidepressant to accelerate clinical response in patients with nonrefractory depression.
Six studies were identified. All were conducted with triiodothyronine (T(3)) and a tricyclic antidepressant. Five of the six studies found T(3) to be significantly more effective than placebo in accelerating clinical response. The pooled, weighted effect size index was 0.58, and the average effect was highly significant. Further, the effects of T(3) acceleration were greater as the percentage of women participating in the study increased.
This meta-analysis supports the efficacy of T(3) in accelerating clinical response to tricyclic antidepressants in patients with nonrefractory depression. Furthermore, women may be more likely than men to benefit from this intervention.

1 Bookmark
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A relationship between hypothyroidism and depression has been assumed for many years; however, the true nature of this association has been difficult to define with many conflicting studies. In recent years, our knowledge in this area has increased significantly with large cohort studies and genetically driven studies being published.
    European thyroid journal. 09/2013; 2(3):168-179.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Major depression is a highly prevalent disorder and is predicted to be the second leading cause of disease burden by 2020. Although many antidepressant drugs are currently available, they are far from optimal. Approximately 50% of patients do not respond to initial first line antidepressant treatment, while approximately one third fail to achieve remission following several pharmacological interventions. Furthermore, several weeks or months of treatment are often required before clinical improvement, if any, is reported. Moreover, most of the commonly used antidepressants have been primarily designed to increase synaptic availability of serotonin and/or noradrenaline and although they are of therapeutic benefit to many patients, it is clear that other therapeutic targets are required if we are going to improve the response and remission rates. It is clear that more effective, rapid-acting antidepressants with novel mechanisms of action are required. The purpose of this review is to outline the current strategies that are being taken in both preclinical and clinical settings for identifying superior antidepressant drugs. The realisation that ketamine has rapid antidepressant-like effects in treatment resistant patients has reenergised the field. Further, developing an understanding of the mechanisms underlying the rapid antidepressant effects in treatment-resistant patients by drugs such as ketamine may uncover novel therapeutic targets that can be exploited to meet the Olympian challenge of developing faster, better and stronger antidepressant drugs.
    European Journal of Pharmacology 08/2014; · 2.68 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Auf einer Depressionsstation eines Bezirkskrankenhauses wurden 28 Patienten nach 6 antidepressiven Strategien mit L-Thyroxin-Dosen von durchschnittlich 350 µg/Tag behandelt. Es kam bei 39,3% zu mäßiger und bei 21,5% zu sehr guter Besserung, gemessen am HAMD-21-Score ≤16 bzw. ≤8 und der klinischen Einschätzung. Bei 39,3% musste die Therapie wegen Erfolglosigkeit oder Nebenwirkungen abgebrochen werden. Nach 45,2 Wochen erfolgte eine Nachuntersuchung aller Schilddrüsenhormon-Responder. 28,6% der Patienten hatten L-Thyroxin abgesetzt. Bei den Therapieabbrechern gab es mit 62,5% signifikant mehr stationäre Aufenthalte als bei den Weiterbehandelten (0%), allerdings fand sich kein Unterschied in 2 verschiedenen subjektiven Ratings. Im Gegensatz zur Literatur, die bei 70 vorwiegend bipolaren Patienten keine schwerwiegenden Nebenwirkungen beschrieb, traten Herzrhythmusstörungen stationär in 10,7% und ambulant katamnestisch in weiteren 7,1% der Fälle in einer Stärke auf, die zum Absetzen führte. Insgesamt scheint daher eine systematische Untersuchung der L-Thyroxin-Hochdosistherapie bei therapieresistenten Depressionen erfolgversprechend und notwendig.
    Der Nervenarzt 03/2004; 75(3). · 0.86 Impact Factor